Study to investigate effectiveness of early-stage pancreatic cancer detection using patented exosome-isolation technology
Biological Dynamics, a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma (PDAC).
The collaboration will test retrospective samples from over 200 patients starting this month. The ExoVerita™ platform is being investigated at NYU Langone Health, among other premier institutions, with a goal of advancing treatment options for high-risk PDAC patients.
“Pancreatic cancer is predicted to be the second leading cause of cancer-related deaths by 2030. Exploring new technologies that can detect cancers sooner in high-risk patients is critical to improving patient outcomes and the quality-of-life years following diagnosis,” says principal investigator, Diane Simeone, MD, surgical oncologist and director, pancreatic cancer center at NYU Langone’s Perlmutter Cancer Center. “I am very interested in collaborating with Biological Dynamics to advance research in developing an early detection blood-based test for pancreatic cancer.”
“The collaboration between Biological Dynamics and NYU Langone Health will bring new perspectives about patients diagnosed with cancer as well as those at high-risk of eventually developing disease. With our recently announced ExoLuminate™ registry trial (NCT05625529), which will determine how our PDAC lab developed test (LDT) performs in prospective at-risk populations, we are thrilled to work with Dr. Simeone on the development of our technology and on future publications,” said Heath Balcer, PhD, Director of Strategic Alliances and Partnerships at Biological Dynamics.
“The current standard of care for early detection is imaging, which has economic and geographic limitations that inhibit surveillance accessibility. Our exosome-isolation technology focuses on PDAC-associated protein biomarkers which are highly abundant in blood, allowing early disease detection. Biological Dynamics’ proprietary Alternating Current Electrokinetics (ACE) technology exclusively isolates exosomes, then detects the concentration of individual protein biomarkers specific to PDAC. Our goal is to improve outcomes for high-risk patients predisposed to pancreatic cancer,” concluded Dr. Balcer.
Source – BusinessWire